GlassScriptPhysician profile
Philip M Barasch
NPI 1295762029
$17,197.03
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,038 · 2020: $3,132 · 2021: $4,682 · 2022: $3,218 · 2023: $2,090 · 2024: $38.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079 · Education: $48.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.24 |
| Education | $48.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,779.89 | 2021-2024 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $1,410.45 | 2019-2023 | Briviact, Nayzilam |
| Biogen, INC. | $1,313.15 | 2019-2023 | Vumerity |
| Novartis Pharmaceuticals Corporation | $1,021.20 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $984.85 | 2019-2023 | Austedo Xr, Ajovy |
| Sk Life Science, INC. | $829.56 | 2020-2023 | |
| Allergan, INC. | $799.71 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $779.79 | 2019-2023 | Ultomiris |
| Genentech USA, INC. | $774.68 | 2019-2023 | Ocrevus |
| Lilly USA, LLC | $542.07 | 2019-2023 | Amyvid |
| Genzyme Corporation | $512.67 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $499.08 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $494.16 | 2019-2023 | Rytary, Lyvispah |
| Emd Serono, INC. | $368.97 | 2019-2023 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $361.54 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Barasch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.